Wellcome Trust

Cultivarium develops open-source tools for life scientists to expand access to novel microorganisms and research.

RenBio is focused on developing innovative antibody-based therapeutic solutions aimed at treating cancer and inflammatory diseases. The company utilizes its proprietary MYO technology to create antibody therapeutics that address a range of conditions, including rare diseases, viral infections, and autoimmune disorders. This platform is designed to be compatible with any antibody and serves as a versatile delivery system, addressing existing manufacturing and delivery challenges in the field of antibody therapeutics. By leveraging its advanced technology, RenBio aims to transform the landscape of antibody treatments and improve outcomes for patients.

Vaxxas is a biotechnology company based in Brisbane, Australia, that specializes in developing a needle-free vaccination technology aimed at transforming vaccine delivery. The company's innovative system employs an array of vaccine-coated micro projections that penetrate the outer layers of the skin when applied with a specialized applicator device. This approach allows for direct deposition of vaccines among a dense concentration of immune cells in the skin. Additionally, Vaxxas utilizes proprietary dry-coating technology to minimize or eliminate the need for refrigeration during the storage and transport of vaccines, thereby alleviating the logistical challenges associated with maintaining the cold chain. Founded in 2011, Vaxxas aims to enhance global vaccination efforts through its novel delivery system.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

data.org seeks to democratize and reimagine the use of data science to tackle society’s greatest challenges and improve lives across the globe. Our current initiatives aim to advance inclusive growth, build capacity, mitigate and adapt to climate change and fight pandemics.

Generate Capital, Inc. is a specialty finance company focused on building, owning, and operating sustainable infrastructure across various sectors, including energy storage, solar power, energy efficiency, and water resources. Headquartered in San Francisco, California, the company was established in 2014 and aims to deliver affordable and reliable resource solutions. Generate Capital provides a range of financial products, including asset-backed lending, project finance, and tailored financing options, to support technology manufacturers, project developers, and contractors. By partnering with these stakeholders, Generate Capital facilitates the growth of scalable businesses in renewable energy and sustainability, enabling clients to secure funding and generate revenue effectively.

Oxitec Limited is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative solutions for controlling insect pests that transmit diseases and damage crops. Founded in 2002, the company employs proprietary genetic technology to enhance the effectiveness and safety of pest control methods, particularly the Sterile Insect Technique (SIT). Oxitec's products include various genetically modified strains of insects, such as the Aedes aegypti mosquito and the Diamondback moth, designed to reduce populations of disease-carrying and crop-damaging species. These strains are engineered for specific environments in Asia and Latin America and include features like female lethality and fluorescent markers for easy identification. With a mosquito production facility in Brazil, Oxitec aims to provide sustainable, non-toxic alternatives for pest management, thereby contributing to global health and agricultural productivity while minimizing environmental impact.

TAE Technologies, Inc. is a company focused on developing clean fusion energy through advanced particle accelerator and plasma physics. Founded in 1998 and headquartered in Foothill Ranch, California, with an additional office in Rancho Santa Margarita, TAE Technologies aims to create a new source of energy derived from natural processes that generates no harmful byproducts. With over two decades of research, the company is dedicated to commercializing safe and cost-effective fusion power solutions. TAE Technologies also contributes to advancements in power management, electric mobility, and life sciences, addressing the global energy demand while promoting sustainable and carbon-free energy alternatives.

ThinkSono Ltd is a London-based company that specializes in developing software for diagnosing deep vein thrombosis (DVT) at the point of care. Founded in 2016, the company has created an automatic diagnostic system that utilizes deep learning technologies. This innovative system guides healthcare professionals in placing a portable ultrasound scanner on the skin to capture images of underlying blood vessels. The software then analyzes these images, allowing doctors to make a DVT diagnosis within ten minutes, significantly enhancing the efficiency of patient care.

Transformative AI Limited, established in 2016 and based in London, United Kingdom, focuses on developing a healthcare platform that utilizes a patent-pending algorithm to predict the onset of sudden cardiac arrest. This innovative technology enables the collection and translation of clinical data into real-time predictive assessments, allowing patients and healthcare providers to identify life-threatening medical events before they occur. By providing advanced warnings, the platform empowers healthcare professionals to prepare for timely interventions, ultimately aiming to enhance patient outcomes and promote longer, healthier lives.

Verne Global, Inc. is a provider of computing solutions specializing in colocation and high-performance computing (HPC)-as-a-Service. Founded in 2006 and based in Arlington, Virginia, the company operates an environmentally-friendly data center campus in Keflavik, Iceland, which has been operational since 2012. This 45-acre facility, built on the site of a former NATO Command Center, was designed to address the challenges of rising power costs and carbon emissions in the data center industry. By utilizing renewable energy sources, including geothermal and hydroelectric power, Verne Global offers a competitively priced, carbon-neutral energy solution. The strategic location of the campus allows global clients to benefit from affordable power while ensuring reliability, making it an appealing option for industries such as artificial intelligence, earth sciences, engineering, financial services, life sciences, and scientific research. Verne Global operates as a subsidiary of Verne Holdings ehf.

Mologic Ltd. is a UK-based company specializing in the development of diagnostic products primarily for the research market. Founded in 2003 by a father-son team, the company is committed to enhancing patient care and advancing research in various fields, including clinical research, diagnostic development, and wound care. Mologic offers a range of diagnostic tools, such as lateral flow kits for measuring Alpha-1 antitrypsin and desmosine in urine, as well as fMLP assay kits for detecting fMLP in human urine. In addition to its product offerings, the company provides services in assay and reagent development, clinical evaluation studies, and the creation of high-performance antibodies for challenging targets. Mologic aims to make significant contributions to healthcare and education through its innovative research and development efforts.

Prokarium Limited is a biopharmaceutical company based in London, United Kingdom, specializing in the development of vaccination and cancer immunotherapy solutions utilizing synthetic biology. The company’s product pipeline includes Vaxonella, which is designed to enhance immune responses through its unique delivery method involving micro fold cells in the small intestine. Prokarium is also working on vaccines targeting Clostridium difficile, Chlamydia trachomatis, plague, and enteric fever. With a focus on microbial immunotherapy, Prokarium aims to revolutionize cancer treatment, particularly in bladder cancer, by creating immune-driven, long-lasting antitumor effects. Founded in 2007, Prokarium is committed to advancing the field of immuno-oncology through innovative approaches that harness the power of synthetic biology.

Kineta, Inc. is a clinical stage biotechnology company based in Seattle, Washington, focused on the development of immunology-based therapeutics for oncology, neuroscience, and virology. The company is advancing a range of innovative therapies, including KCP-506, a non-opioid antagonist for chronic pain, and LHF-535, an oral antiviral targeting Lassa and other arenaviruses by inhibiting viral entry and replication. Kineta is also engaged in developing next-generation immunotherapies, exemplified by KVA12.1, a VISTA blocking immunotherapy designed to reprogram the immune system to combat cancer. With strategic partnerships with notable organizations like Pfizer and Genentech, Kineta aims to leverage its expertise in antiviral therapies and immune modulation to address significant medical challenges. Formerly known as Lecura, Inc., the company was founded in 2007.

Integrated BioTherapeutics is a biotechnology company that focuses on discovering novel vaccines and therapeutics for emerging infectious diseases. Its antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines, and a variety of other product candidates for emerging viruses.

Karuna Therapeutics is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing innovative therapies for neuropsychiatric disorders and pain. Its lead product candidate, KarXT, is an oral modulator that has completed a Phase II clinical trial for treating acute psychosis in schizophrenia patients and is undergoing a Phase Ib clinical trial for various central nervous system disorders, including cognitive and negative symptoms of schizophrenia, Alzheimer’s, and dementia-related psychosis. The company is also developing additional muscarinic-targeted drug candidates to address unmet medical needs in these areas. Founded in 2009, Karuna Therapeutics has established partnerships with organizations such as Eli Lilly and Company and PureTech Health LLC, focusing on advancing its drug discovery efforts through collaborations with Charles River Laboratories and PsychoGenics Inc.

Karuna Therapeutics is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing innovative therapies for neuropsychiatric disorders and pain. Its lead product candidate, KarXT, is an oral modulator that has completed a Phase II clinical trial for treating acute psychosis in schizophrenia patients and is undergoing a Phase Ib clinical trial for various central nervous system disorders, including cognitive and negative symptoms of schizophrenia, Alzheimer’s, and dementia-related psychosis. The company is also developing additional muscarinic-targeted drug candidates to address unmet medical needs in these areas. Founded in 2009, Karuna Therapeutics has established partnerships with organizations such as Eli Lilly and Company and PureTech Health LLC, focusing on advancing its drug discovery efforts through collaborations with Charles River Laboratories and PsychoGenics Inc.

Karuna Therapeutics is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing innovative therapies for neuropsychiatric disorders and pain. Its lead product candidate, KarXT, is an oral modulator that has completed a Phase II clinical trial for treating acute psychosis in schizophrenia patients and is undergoing a Phase Ib clinical trial for various central nervous system disorders, including cognitive and negative symptoms of schizophrenia, Alzheimer’s, and dementia-related psychosis. The company is also developing additional muscarinic-targeted drug candidates to address unmet medical needs in these areas. Founded in 2009, Karuna Therapeutics has established partnerships with organizations such as Eli Lilly and Company and PureTech Health LLC, focusing on advancing its drug discovery efforts through collaborations with Charles River Laboratories and PsychoGenics Inc.

PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. The company's flagship product, PredictSURE IBD, is a diagnostic tool that evaluates patients with inflammatory bowel disease, including Crohn's disease and ulcerative colitis. This test utilizes a small blood sample to identify patients at diagnosis who are at risk of severe, relapsing disease, thereby enabling healthcare providers to recommend early biologic therapy to those who would benefit most. By providing crucial prognostic information, PredictImmune aims to enhance treatment decision-making for physicians and improve outcomes for patients suffering from these conditions. The company's research is rooted in leading studies from Cambridge University, reflecting its commitment to advancing personalized medicine in the field of inflammatory bowel disease.

DoorDash, Inc. is a logistics platform that connects consumers, merchants, and delivery personnel, primarily in the United States and Europe. Founded in 2013 and headquartered in San Francisco, the company initially launched as PaloAltoDelivery.com before rebranding to DoorDash, Inc. in 2015. DoorDash offers a marketplace that allows local and national restaurants, as well as other businesses such as grocery stores and retailers, to reach customers through online ordering for pickup or delivery. The company's services include customer acquisition, delivery logistics, insights and analytics, payment processing, and customer support. Additionally, DoorDash operates DoorDash Drive, a white-label logistics service that further enhances its delivery capabilities. Through its platform, DoorDash aims to transform local businesses and strengthen community connections by building a robust last-mile delivery infrastructure.

CorInnova Incorporated, founded in 2004 and based in Houston, Texas, specializes in device-based therapies aimed at treating congestive heart failure. The company is known for its innovative non-blood-contacting soft robotic cardiac assist device, which has the potential to significantly increase the number of heart failure patients eligible for life-saving device therapies. By focusing on advanced technological solutions, CorInnova seeks to improve outcomes for individuals suffering from this serious condition.

Instacart is a prominent grocery delivery service operating in the United States and Canada, facilitating rapid deliveries of groceries and home essentials, often within an hour. The company partners with a variety of local and national grocers, including well-known brands such as Safeway, Whole Foods, and Costco, allowing customers to select from over 500,000 items and combine orders from multiple stores. Instacart employs a network of approximately 600,000 independent contractors who pick and deliver items directly to customers' homes. In addition to its delivery services, Instacart generates revenue by charging fees based on order value and by offering advertising opportunities primarily to consumer-packaged goods companies. With nearly 8 million monthly active users, Instacart has established itself as a leading platform in the grocery delivery market.

ResearchGate GmbH is an online professional network platform designed for scientific researchers globally, founded in 2008 and headquartered in Berlin, Germany. The platform facilitates the sharing and discovery of scientific knowledge, enabling over 20 million researchers to connect, collaborate, and advance their careers. Users can access and share publications, publish data, track citation metrics, and utilize research-focused job boards. Additionally, ResearchGate allows users to pose questions and receive answers related to their research challenges, fostering a collaborative environment among peers and specialists. The company aims to make research accessible and promote connections within the scientific community through its web and mobile applications.

Exonate Limited is a private biotech company based in Duxford, United Kingdom, specializing in the discovery and development of small molecule drugs aimed at modulating alternative messenger RNA splicing for ophthalmological applications. Founded in 2013, the company emerged from the University of Nottingham and is focused on addressing retinal vascular diseases, particularly diabetic macular oedema (DMO) and wet age-related macular degeneration (wAMD). Exonate's lead program utilizes small molecule inhibitors that selectively target serine/threonine-protein kinase 1 to inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) splice variants. This innovative approach aims to improve therapeutic outcomes and offers a potential alternative to current treatment methods, such as anti-VEGF injections and laser surgery. With a preclinical candidate drug already nominated, Exonate is advancing its research through regulatory toxicology and safety pharmacology studies to facilitate clinical evaluation. The company is backed by an experienced management team with expertise in medicine and drug development.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, focused on discovering and developing fully human monoclonal antibody therapeutics. The company utilizes its proprietary Kymouse platform, which is part of the broader IntelliSelect® integrated platforms, to target difficult and novel drug challenges in various therapeutic areas, including immuno-oncology and immune-mediated diseases. Kymab’s technology allows for the generation of a diverse range of human antibodies, enhancing the potential for novel therapies in treating conditions such as cancer and autoimmune disorders. The company has established strategic collaborations, including partnerships with Heptares Therapeutics and LifeArc, to further its research and development efforts. Founded in 2009, Kymab Limited operates as a subsidiary of Kymab Group Limited.

Acesion Pharma ApS is a biotech company based in Copenhagen, Denmark, founded in 2011. The company specializes in the development of medical drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Acesion Pharma focuses on creating SK channel inhibitors, which target specific ion channels in heart cells that are essential for generating the electrical signals that regulate heart rhythm. By inhibiting these channels, the company aims to provide safe and tolerable chronic treatments that prevent the recurrence of AF and support the maintenance of a normal heart rhythm.

Phononic, Inc. specializes in the design, prototyping, and manufacturing of innovative cooling and heating solutions, focusing on solid-state technology. Founded in 2008 and based in Durham, North Carolina, the company develops thermoelectric devices and heat pumps that replace traditional compressor technology in various applications. Its products are utilized for electronics cooling in sectors such as optoelectronics and high-performance computing, as well as in healthcare, residential, and commercial refrigeration. Phononic's thermoelectric chips, made from bismuth telluride, offer sustainable and efficient temperature control without the use of toxic refrigerants, making them suitable for industries that require precise temperature management while reducing energy consumption. The company's approach aims to deliver smart and sustainable solutions for diverse climate control needs.

Pearl is dedicated to bringing the latest advanced driver assistance features to all drivers on the road today. Products created by the team at Pearl leverage the very same technologies that are the building blocks of the autonomous vehicle. By deploying these features in the aftermarket, Pearl enables more consumers to have access to these key technologies.

DoorDash, Inc. is a logistics platform that connects consumers, merchants, and delivery personnel, primarily in the United States and Europe. Founded in 2013 and headquartered in San Francisco, the company initially launched as PaloAltoDelivery.com before rebranding to DoorDash, Inc. in 2015. DoorDash offers a marketplace that allows local and national restaurants, as well as other businesses such as grocery stores and retailers, to reach customers through online ordering for pickup or delivery. The company's services include customer acquisition, delivery logistics, insights and analytics, payment processing, and customer support. Additionally, DoorDash operates DoorDash Drive, a white-label logistics service that further enhances its delivery capabilities. Through its platform, DoorDash aims to transform local businesses and strengthen community connections by building a robust last-mile delivery infrastructure.

Quethera Limited is a gene therapy company based in Canterbury, United Kingdom, founded in 2013. The company specializes in developing innovative treatments for glaucoma and other ophthalmic diseases, particularly aimed at reducing progressive visual loss associated with these conditions. Quethera collaborates with leading experts in the field of glaucoma to design and conduct clinical trials that evaluate the efficacy and safety of its novel therapies, especially for patients who experience accelerated visual field loss. With a strong foundation in gene therapeutic design and development, Quethera is advancing its research pipeline from preclinical testing into clinical development, striving to enhance treatment options for patients suffering from common blinding eye diseases. As of August 2018, Quethera operates as a subsidiary of Astellas Pharma Inc.

Mucosis B.V. is a clinical-stage biotechnology company based in the Netherlands, focused on developing innovative mucosal vaccines that can be administered needle-free through the nose or mouth. Its lead product candidate, SynGEM, is an intranasal vaccine aimed at preventing respiratory syncytial virus (RSV) infection. The company's vaccines utilize the patented Mimopath technology, which facilitates a more natural immune response and offers broad protection against infectious diseases. This approach has shown promise in both animal and human studies, particularly with the FluGEM vaccine candidate, by targeting the innate immune system through Toll-like receptor 2 (TLR2) to activate the adaptive immune response. Mucosis aims to address various infectious diseases, including RSV, pneumococci, and influenza.

MediSieve Ltd. is a medical device company based in London, United Kingdom, focused on developing Magnetic Blood Filtration (MBF) technology to treat blood-borne diseases. Established in 2014, the company has created a blood filtration device that magnetically removes infected blood cells, enabling the treatment of conditions such as malaria, leukemia, and sepsis. The MBF system operates by circulating a patient’s blood through an external loop where targeted magnetic particles bind to disease-relevant targets. The blood then passes through a magnetic filter that captures these particles and bound targets, allowing the unaffected blood to be returned to the patient. MediSieve's innovative approach also aims to enhance the safety and efficacy of existing therapies while expanding the range of treatable diseases. The company operates from the Imperial Incubator in White City, London, where it has specialized laboratory facilities for product development and validation.

Elastagen is a clinical stage medical company focused on developing products derived from the human protein tropoelastin, which is essential for the elasticity and resilience of various tissues in the body, including skin and blood vessels. The company has created a synthetic version of elastin that mimics the natural protein found in humans. Its advanced product pipeline targets applications in skin rejuvenation, scar remodeling, and tissue repair. With injectable synthetic human elastin and chemically cross-linked tropoelastin for aesthetic uses, Elastagen aims to help patients maintain skin elasticity and suppleness. Founded after acquiring intellectual property rights to elastin technology developed by Professor Weiss at the University of Sydney, Elastagen has successfully secured funding from prominent life science venture capital firms and expanded its operations to include production in Europe and clinical activities in the UK.

Klarna Inc. is an e-commerce payment solutions provider that serves both merchants and consumers, specializing in flexible payment options. Founded in 2005 and headquartered in Columbus, Ohio, with additional offices in New York City, Klarna offers a range of services including direct payments, pay-after-delivery options, and installment plans. The company is recognized for its "buy now, pay later" model, allowing shoppers to finance their retail purchases with interest-free payments. Klarna also enhances the shopping experience through its app, which offers features such as cashback rewards and on-site messaging for retailers. As a regulated bank, Klarna operates under a framework that supports a variety of payment processing and dispute resolution services, aiming to make transactions simple, safe, and smooth for users.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious infections. The company's lead product candidate, XENLETA, is the first systemic pleuromutilin antibiotic approved by the U.S. Food and Drug Administration for the treatment of community-acquired bacterial pneumonia. In addition to XENLETA, Nabriva is developing CONTEPO, a potential first-in-class epoxide antibiotic aimed at treating complicated urinary tract infections, including acute pyelonephritis. The company is also involved in clinical trials for other indications, including pediatric infections and sexually transmitted infections. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva was previously known as Nabriva Therapeutics Forschungs GmbH before rebranding in 2007.

DoorDash, Inc. is a logistics platform that connects consumers, merchants, and delivery personnel, primarily in the United States and Europe. Founded in 2013 and headquartered in San Francisco, the company initially launched as PaloAltoDelivery.com before rebranding to DoorDash, Inc. in 2015. DoorDash offers a marketplace that allows local and national restaurants, as well as other businesses such as grocery stores and retailers, to reach customers through online ordering for pickup or delivery. The company's services include customer acquisition, delivery logistics, insights and analytics, payment processing, and customer support. Additionally, DoorDash operates DoorDash Drive, a white-label logistics service that further enhances its delivery capabilities. Through its platform, DoorDash aims to transform local businesses and strengthen community connections by building a robust last-mile delivery infrastructure.

Verne Global, Inc. is a provider of computing solutions specializing in colocation and high-performance computing (HPC)-as-a-Service. Founded in 2006 and based in Arlington, Virginia, the company operates an environmentally-friendly data center campus in Keflavik, Iceland, which has been operational since 2012. This 45-acre facility, built on the site of a former NATO Command Center, was designed to address the challenges of rising power costs and carbon emissions in the data center industry. By utilizing renewable energy sources, including geothermal and hydroelectric power, Verne Global offers a competitively priced, carbon-neutral energy solution. The strategic location of the campus allows global clients to benefit from affordable power while ensuring reliability, making it an appealing option for industries such as artificial intelligence, earth sciences, engineering, financial services, life sciences, and scientific research. Verne Global operates as a subsidiary of Verne Holdings ehf.

Phononic, Inc. specializes in the design, prototyping, and manufacturing of innovative cooling and heating solutions, focusing on solid-state technology. Founded in 2008 and based in Durham, North Carolina, the company develops thermoelectric devices and heat pumps that replace traditional compressor technology in various applications. Its products are utilized for electronics cooling in sectors such as optoelectronics and high-performance computing, as well as in healthcare, residential, and commercial refrigeration. Phononic's thermoelectric chips, made from bismuth telluride, offer sustainable and efficient temperature control without the use of toxic refrigerants, making them suitable for industries that require precise temperature management while reducing energy consumption. The company's approach aims to deliver smart and sustainable solutions for diverse climate control needs.

Omniox is a biopharmaceutical company focused on developing innovative treatments for hypoxic diseases, which occur when tissues receive insufficient oxygen. This condition is linked to serious health issues, including various cancers and cardiovascular diseases. The company utilizes a proprietary protein-based platform technology known as H-NOX, which is designed to deliver oxygen and nitric oxide directly to hypoxic tissues. By specifically targeting these areas, Omniox aims to restore normal tissue function, potentially improving patient outcomes and offering new therapeutic options. Through its work, Omniox seeks to advance oxygen-based therapies that address the challenges posed by diseases associated with low oxygen levels.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

The AirStrip Technologies platform securely delivers critical patient information, including virtual real-time waveform data, directly from hospital monitoring systems to a doctor or nurse's smart phone, laptop or desktop. The platform is completely reusable, scalable and data independent, and can be employed throughout the healthcare enterprise.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, focused on discovering and developing fully human monoclonal antibody therapeutics. The company utilizes its proprietary Kymouse platform, which is part of the broader IntelliSelect® integrated platforms, to target difficult and novel drug challenges in various therapeutic areas, including immuno-oncology and immune-mediated diseases. Kymab’s technology allows for the generation of a diverse range of human antibodies, enhancing the potential for novel therapies in treating conditions such as cancer and autoimmune disorders. The company has established strategic collaborations, including partnerships with Heptares Therapeutics and LifeArc, to further its research and development efforts. Founded in 2009, Kymab Limited operates as a subsidiary of Kymab Group Limited.

Integrated Diagnostics Inc. specializes in the development of laboratory-based blood molecular diagnostic tools designed to assist physicians in the early detection of complex diseases through non-invasive blood tests. The company's flagship product, Xpresys Lung, provides objective information for assessing pulmonary nodules by monitoring multiple disease molecular markers simultaneously. Founded in 2005 and based in Seattle, Washington, Integrated Diagnostics aims to leverage emerging technologies to create a pipeline of innovative diagnostic products that facilitate the management of serious conditions such as cancer, diabetes, and Alzheimer's. The company operates under the principle that a systems view of disease, involving networks of proteins, genes, and other molecules, is essential for effective diagnosis and prognosis. Integrated Diagnostics is a subsidiary of Biodesix, Inc. and has established a strategic partnership with Agilent Technologies.

Acesion Pharma ApS is a biotech company based in Copenhagen, Denmark, founded in 2011. The company specializes in the development of medical drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Acesion Pharma focuses on creating SK channel inhibitors, which target specific ion channels in heart cells that are essential for generating the electrical signals that regulate heart rhythm. By inhibiting these channels, the company aims to provide safe and tolerable chronic treatments that prevent the recurrence of AF and support the maintenance of a normal heart rhythm.

Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections and challenging viral infections. Founded in 2010 and based in Malvern, Pennsylvania, the company specializes in developing antibacterial drugs to combat resistant infections commonly encountered in hospital and community settings, such as those caused by MRSA, Pseudomonas spp., and Salmonella spp. Venatorx employs innovative chemical approaches to create treatments that exhibit selective and potent activity against various resistant bacterial strains, thereby providing healthcare professionals with broader treatment options to address significant unmet medical needs.

Treventis Corporation specializes in developing small molecule drugs aimed at treating and preventing protein misfolding diseases, particularly focusing on tauopathies related to Alzheimer’s disease. The company employs a proprietary discovery engine called Common Conformational Morphology (CCM), which integrates advanced in silico modeling with extensive expertise in drug development across various biological systems. This innovative approach allows Treventis to identify druggable active sites in misfolded protein targets, facilitating the rational design of therapeutic compounds. The lead program is centered around anti-misfolding small molecules that target tau proteins, while additional CCM-driven initiatives are underway in oncology and other neurodegenerative disorders, highlighting the versatility of their technology platform. The drugs developed by Treventis aim to effectively neutralize misfolded proteins, potentially blocking the progression of amyloid toxicity and offering a treatment option for Alzheimer’s patients with minimal side effects.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Trino Therapeutics is a drug discovery and early development company specializing in anti-inflammatory therapeutics. The firm is focused on creating drug candidates from a unique class of compounds based on indane dimers derived from a Taiwanese fern. Its lead candidate aims to be a first-in-class treatment for inflammatory bowel disease (IBD), targeting conditions such as ulcerative colitis and Crohn’s disease. Additionally, Trino's novel drug class exhibits broad anti-inflammatory potential, making it suitable for various applications in dermatology, pulmonary conditions, and autoimmune diseases.

Canbex Therapeutics, based in London, United Kingdom, focuses on developing peripherally-acting cannabinoid agonists aimed at treating spasticity associated with multiple sclerosis and other neurodegenerative disorders. Founded in 2005, the company is committed to addressing the debilitating symptoms of spasticity, which include involuntary muscle spasms and stiffness. Canbex's lead program seeks to enhance the quality of life for patients suffering from this challenging and incurable condition, with the aim of establishing a new standard in the management of spasticity.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Haemostatix Ltd., founded in 2003 and based in Nottingham, United Kingdom, specializes in developing a peptide-based platform technology aimed at addressing surgical bleeding and advancing tissue repair and regenerative medicine. The company originated as a spin-out from the University of Leicester and was co-founded by Sarah Middleton and Professor Alison Goodall. Its product pipeline includes PeproStat, a coagulant applied directly to wounds to effectively manage bleeding during surgical procedures. Haemostatix also focuses on creating various forms of hemostats, including liquid and transparent gel formulations, which enhance the speed and safety of bleeding control for healthcare professionals. As of May 2016, Haemostatix operates as a subsidiary of Ergomed plc.

Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in the discovery, development, and commercialization of novel antibiotics aimed at treating serious infectious diseases. The company focuses on addressing Clostridium difficile infection (CDI) with its lead product candidate, ridinilazole, which is currently undergoing Phase III clinical trials. Additionally, Summit is developing the DDS-01 series to combat infections caused by Neisseria gonorrhoeae and the DDS-04 series targeting Enterobacteriaceae. With operations in the United States and Europe, Summit Therapeutics aims to establish new standards of care for patients while creating value for payors and healthcare providers. Founded in 2003, the company is committed to advancing innovative treatments for infectious diseases.

The AirStrip Technologies platform securely delivers critical patient information, including virtual real-time waveform data, directly from hospital monitoring systems to a doctor or nurse's smart phone, laptop or desktop. The platform is completely reusable, scalable and data independent, and can be employed throughout the healthcare enterprise.

Siluria Technologies is a materials innovation company focused on addressing global challenges in the natural gas, chemicals, and fuel sectors. By leveraging advancements in nanotechnology, biotechnology, and chemical engineering, Siluria has created a platform that enables the efficient production of chemicals and fuels from natural gas, which is a more abundant and cost-effective resource than oil. The company's technology allows for the conversion of natural gas and low-value by-products into higher-value products, including liquid fuels such as gasoline, diesel, and jet fuel. Siluria's research and development teams are actively working towards commercializing their technology through partnerships with leading chemical and fuel companies, facilitating pilot-scale production to integrate their innovations into existing industry infrastructure.

Kuur Therapeutics Limited is a biopharmaceutical company focused on developing, manufacturing, and commercializing CAR-NKT cell immunotherapies for cancer treatment. The company is advancing a pipeline of immune cell products, including KUR-501 for neuroblastoma, KUR-502 for hematological malignancies, and KUR-503 for liver cancer. Kuur Therapeutics specializes in engineered off-the-shelf CAR-NKT cell therapies that leverage the natural biology of a specific subset of cytotoxic T cells known as natural killer T cells. This innovative approach aims to provide effective treatment options for a wide range of solid and hematological tumors. The company conducts clinical trials to demonstrate the efficacy of its CAR-NKT cell products, thereby striving to transform cancer care. Founded in 2005 and based in London, Kuur Therapeutics was previously known as Cell Medica Limited before its rebranding in February 2020.

Castlight is on a mission to make it as easy as humanly possible for people to navigate the healthcare system, and live happier, healthier, more productive lives. They as a leader in healthcare navigation, we provide a world-class digital platform with a team of clinical, and benefits experts to help members easily connect, and engage with the right programs and care, at the right time. Castlight partners with companies, and health plans to transform employee, and member benefits into one comprehensive health, and wellbeing experience to deliver better health outcomes, and maximize returns on healthcare investments.

Sapphire Energy, Inc. is a San Diego-based company that specializes in producing renewable solutions from algae, pioneering the Green Crude industry. Founded in 2007, the company utilizes sunlight, carbon dioxide, non-potable water, and non-arable land to cultivate algae in outdoor ponds. This biomass can be converted into high-value products, including oils, aquaculture feeds, animal feeds, and fuels, without relying on food crops or potable water. Sapphire Energy's innovative processes not only enhance and replace traditional petroleum-based products but also operate compatibly with existing infrastructure, offering a low carbon and scalable alternative to conventional biofuels. The company has established a research and development facility in Las Cruces, New Mexico, and is developing an Integrated Algal BioRefinery in Columbus, New Mexico, to further its mission of creating sustainable energy solutions.

Integrated Diagnostics Inc. specializes in the development of laboratory-based blood molecular diagnostic tools designed to assist physicians in the early detection of complex diseases through non-invasive blood tests. The company's flagship product, Xpresys Lung, provides objective information for assessing pulmonary nodules by monitoring multiple disease molecular markers simultaneously. Founded in 2005 and based in Seattle, Washington, Integrated Diagnostics aims to leverage emerging technologies to create a pipeline of innovative diagnostic products that facilitate the management of serious conditions such as cancer, diabetes, and Alzheimer's. The company operates under the principle that a systems view of disease, involving networks of proteins, genes, and other molecules, is essential for effective diagnosis and prognosis. Integrated Diagnostics is a subsidiary of Biodesix, Inc. and has established a strategic partnership with Agilent Technologies.

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.

Sapiens International Corporation is a provider of software solutions tailored for the insurance industry, with an expanding focus on the financial services sector. The company delivers comprehensive software and professional services across various markets, including property and casualty, reinsurance, life, pension and annuities, and workers' compensation. Sapiens also offers decision management solutions that enable financial organizations to implement system and process changes safely. Additionally, the company provides project delivery and implementation services to support its software solutions. Sapiens operates in North America, Europe, and other regions, positioning itself as a key player in the insurance and financial services industries.

Sapiens Steering Brain Stimulation GmbH is a medical device company focused on advancing deep brain stimulation (DBS) therapy. Founded in 2011 as a spin-out of Royal Philips Electronics, the company aims to enhance patient comfort and therapeutic outcomes with its innovative, high-resolution, and MRI-compatible DBS system. Sapiens specializes in developing a comprehensive DBS solution that includes navigation and steering software, as well as implants specifically designed for patients with Parkinson's disease. With offices in Eindhoven, the Netherlands, and Munich, Germany, Sapiens leverages patented technologies to deliver effective and precise treatment options for individuals suffering from this neurological condition.

Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

Siluria Technologies is a materials innovation company focused on addressing global challenges in the natural gas, chemicals, and fuel sectors. By leveraging advancements in nanotechnology, biotechnology, and chemical engineering, Siluria has created a platform that enables the efficient production of chemicals and fuels from natural gas, which is a more abundant and cost-effective resource than oil. The company's technology allows for the conversion of natural gas and low-value by-products into higher-value products, including liquid fuels such as gasoline, diesel, and jet fuel. Siluria's research and development teams are actively working towards commercializing their technology through partnerships with leading chemical and fuel companies, facilitating pilot-scale production to integrate their innovations into existing industry infrastructure.

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.

Canbex Therapeutics, based in London, United Kingdom, focuses on developing peripherally-acting cannabinoid agonists aimed at treating spasticity associated with multiple sclerosis and other neurodegenerative disorders. Founded in 2005, the company is committed to addressing the debilitating symptoms of spasticity, which include involuntary muscle spasms and stiffness. Canbex's lead program seeks to enhance the quality of life for patients suffering from this challenging and incurable condition, with the aim of establishing a new standard in the management of spasticity.

Beyond Oblivion is a music and technology company founded in 2008 by its CEO, Adam Kidron. Its principle shareholders are Wellcome Trust, News Corporation, Allen & Company, Intertrust Technologies Corporation, and Adam Kidron. Beyond Oblivion's first go-to-market product is boinc. boinc is a magnetic and social music service that distributes a vast legal music library from a cloud (supplied by majors, independents, and artists the world over), and embeds the right to download and PLAY IT ALL within devices like PCs, tablets, autos and smartphones. boinc replaces paid-download, paid subscription, and advertiser-supported services with an inexpensive one-time, lifetime-of-device usage fee - paying copyright owners a micro-royalty per play, no matter if the original file were legally or illegally downloaded.

Wonga is a UK-based online lender specializing in small, short-term cash advances. It uses advanced risk assessment technology to make swift, responsible lending decisions. Customers can customize loan amounts (up to £750) and durations (5 to 30 days) before applying, with funds deposited within minutes. Wonga's fully automated system offers more speed and flexibility than traditional credit options, aiming to help consumers manage temporary cash shortfalls rather than long-term debt. It has been recognized for its innovative technology, winning awards such as the Red Herring Europe 100 and the National Business Awards.

Haemostatix Ltd., founded in 2003 and based in Nottingham, United Kingdom, specializes in developing a peptide-based platform technology aimed at addressing surgical bleeding and advancing tissue repair and regenerative medicine. The company originated as a spin-out from the University of Leicester and was co-founded by Sarah Middleton and Professor Alison Goodall. Its product pipeline includes PeproStat, a coagulant applied directly to wounds to effectively manage bleeding during surgical procedures. Haemostatix also focuses on creating various forms of hemostats, including liquid and transparent gel formulations, which enhance the speed and safety of bleeding control for healthcare professionals. As of May 2016, Haemostatix operates as a subsidiary of Ergomed plc.

ProteinSimple is a prominent company within the Protein Platforms division of Bio-Techne, specializing in innovative solutions for protein analysis. The company develops a comprehensive range of tools designed to assist life science researchers in addressing complex protein analysis challenges, thereby facilitating insights into proteins and their roles in diseases. Its product offerings include advanced immunoassay systems for quantifying protein expression and sophisticated systems for assessing the structure and purity of protein-based therapeutics. Additionally, ProteinSimple provides nano-proteomic analysis systems that enable researchers to measure phospho-protein signaling and activation in small biological samples, allowing for the quantification of phospho-protein isoforms in various cell types. Through these capabilities, ProteinSimple supports critical research in understanding cellular processes and monitoring drug actions in diverse biological contexts.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, focused on discovering and developing fully human monoclonal antibody therapeutics. The company utilizes its proprietary Kymouse platform, which is part of the broader IntelliSelect® integrated platforms, to target difficult and novel drug challenges in various therapeutic areas, including immuno-oncology and immune-mediated diseases. Kymab’s technology allows for the generation of a diverse range of human antibodies, enhancing the potential for novel therapies in treating conditions such as cancer and autoimmune disorders. The company has established strategic collaborations, including partnerships with Heptares Therapeutics and LifeArc, to further its research and development efforts. Founded in 2009, Kymab Limited operates as a subsidiary of Kymab Group Limited.

Castlight is on a mission to make it as easy as humanly possible for people to navigate the healthcare system, and live happier, healthier, more productive lives. They as a leader in healthcare navigation, we provide a world-class digital platform with a team of clinical, and benefits experts to help members easily connect, and engage with the right programs and care, at the right time. Castlight partners with companies, and health plans to transform employee, and member benefits into one comprehensive health, and wellbeing experience to deliver better health outcomes, and maximize returns on healthcare investments.

Biota Holdings Limited is an Australian biotechnology company focused on the discovery, development, and commercialization of anti-infective drugs, primarily targeting respiratory diseases such as influenza. The company is known for creating zanamivir, an in-class neuraminidase inhibitor marketed as Relenza for the treatment of seasonal influenza. Biota has also explored treatments for hepatitis C virus infections through nucleoside analogues licensed to Boehringer Ingelheim and is developing candidates for respiratory syncytial virus disease. Currently, Biota is conducting clinical trials for its lead compound targeting human rhinovirus infections in patients with compromised respiratory or immune systems. The company has established a partnership with Daiichi Sankyo to advance the development of second-generation antiviral drugs for influenza and has expanded its portfolio by acquiring antibacterial assets from MaxThera Inc.

Achaogen, Inc. is a biopharmaceutical company focused on developing antibacterial agents to combat multi-drug resistant (MDR) gram-negative infections. The company's primary product, plazomicin, is designed to treat serious bacterial infections caused by MDR enterobacteriaceae, particularly carbapenem-resistant strains. Additionally, Achaogen is working on C-Scape, an orally-administered combination therapy targeting infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established several collaboration agreements, including partnerships with Thermo Fisher Scientific for assay development, and Ionis Pharmaceuticals for the advancement of aminoglycoside antibacterial compounds. The company generates revenue primarily through government contracts for research and development. Founded in 2002 and based in South San Francisco, California, Achaogen filed for Chapter 11 bankruptcy in April 2019, transitioning to a liquidation plan in May 2020.

Mintaka Foundation is finding simple health solutions for developing countries using advanced technology.

Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in the discovery, development, and commercialization of novel antibiotics aimed at treating serious infectious diseases. The company focuses on addressing Clostridium difficile infection (CDI) with its lead product candidate, ridinilazole, which is currently undergoing Phase III clinical trials. Additionally, Summit is developing the DDS-01 series to combat infections caused by Neisseria gonorrhoeae and the DDS-04 series targeting Enterobacteriaceae. With operations in the United States and Europe, Summit Therapeutics aims to establish new standards of care for patients while creating value for payors and healthcare providers. Founded in 2003, the company is committed to advancing innovative treatments for infectious diseases.

Oxagen Limited is a biopharmaceutical company focused on developing and commercializing anti-inflammatory medications for asthma and other chronic allergic conditions. The company specializes in small molecule drugs, including OC000459, an oral CRTH2 antagonist aimed at treating eosinophilic asthma and allergic rhinoconjunctivitis. Oxagen's drug development targets the CRTH2 receptor, which plays a critical role in the initiation and maintenance of allergic responses. In addition to asthma, their pipeline includes treatments for autoimmune diseases, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Founded in 1996 and based in London, Oxagen serves customers in the United Kingdom, Russia, and other countries in the Commonwealth of Independent States.

Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious infections. The company's lead product candidate, XENLETA, is the first systemic pleuromutilin antibiotic approved by the U.S. Food and Drug Administration for the treatment of community-acquired bacterial pneumonia. In addition to XENLETA, Nabriva is developing CONTEPO, a potential first-in-class epoxide antibiotic aimed at treating complicated urinary tract infections, including acute pyelonephritis. The company is also involved in clinical trials for other indications, including pediatric infections and sexually transmitted infections. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva was previously known as Nabriva Therapeutics Forschungs GmbH before rebranding in 2007.

Integrated Diagnostics Inc. specializes in the development of laboratory-based blood molecular diagnostic tools designed to assist physicians in the early detection of complex diseases through non-invasive blood tests. The company's flagship product, Xpresys Lung, provides objective information for assessing pulmonary nodules by monitoring multiple disease molecular markers simultaneously. Founded in 2005 and based in Seattle, Washington, Integrated Diagnostics aims to leverage emerging technologies to create a pipeline of innovative diagnostic products that facilitate the management of serious conditions such as cancer, diabetes, and Alzheimer's. The company operates under the principle that a systems view of disease, involving networks of proteins, genes, and other molecules, is essential for effective diagnosis and prognosis. Integrated Diagnostics is a subsidiary of Biodesix, Inc. and has established a strategic partnership with Agilent Technologies.

PacBio designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes.

Chroma Therapeutics Ltd. is a biotechnology company based in Abingdon, United Kingdom, specializing in the discovery and development of novel small molecule drugs targeting cancer and inflammatory disorders. Founded in 2000, Chroma leverages chromatin biology and innovative cell accumulation techniques to create its product pipeline. Key products include Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor designed for cancer treatment; and CHR-2845, focused on hematological malignancies. The company is recognized for its systematic assembly of intellectual property in chromatin biology and has established a strong network of academic collaborations to enhance its research and development efforts.

VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.

Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.

ProteinSimple is a prominent company within the Protein Platforms division of Bio-Techne, specializing in innovative solutions for protein analysis. The company develops a comprehensive range of tools designed to assist life science researchers in addressing complex protein analysis challenges, thereby facilitating insights into proteins and their roles in diseases. Its product offerings include advanced immunoassay systems for quantifying protein expression and sophisticated systems for assessing the structure and purity of protein-based therapeutics. Additionally, ProteinSimple provides nano-proteomic analysis systems that enable researchers to measure phospho-protein signaling and activation in small biological samples, allowing for the quantification of phospho-protein isoforms in various cell types. Through these capabilities, ProteinSimple supports critical research in understanding cellular processes and monitoring drug actions in diverse biological contexts.

Phico Therapeutics Limited is a biotechnology company based in Bourn, United Kingdom, focused on developing innovative antibiotics to combat antibacterial resistance. Utilizing its SASPject platform, the company delivers anti-bacterial proteins, including small acid-soluble spore proteins, to specific bacterial species through targeted non-delivery vehicles. Phico's product pipeline includes SASPject PT3, an antibiotic aimed at Pseudomonas aeruginosa; SASPject PT4 and PT5, designed for systemic use against Klebsiella pneumonia and Escherichia coli; and SASPject PT1.2, which targets Staphylococcus aureus. Additionally, the company is developing an intravenous-engineered bacteriophage drug intended to treat ventilator-associated pneumonia by using engineered bacterial viruses along with antibacterial proteins to inhibit bacterial reproduction and toxin release. Founded in 2000, Phico Therapeutics is committed to advancing solutions for pressing healthcare challenges posed by antibiotic resistance.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Qwell's goal is to develop a new family of small-molecule drugs, derived from a plant source, that have a potent ability to fight tumors and excess inflammation of skin cells.

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.

Sapphire Energy, Inc. is a San Diego-based company that specializes in producing renewable solutions from algae, pioneering the Green Crude industry. Founded in 2007, the company utilizes sunlight, carbon dioxide, non-potable water, and non-arable land to cultivate algae in outdoor ponds. This biomass can be converted into high-value products, including oils, aquaculture feeds, animal feeds, and fuels, without relying on food crops or potable water. Sapphire Energy's innovative processes not only enhance and replace traditional petroleum-based products but also operate compatibly with existing infrastructure, offering a low carbon and scalable alternative to conventional biofuels. The company has established a research and development facility in Las Cruces, New Mexico, and is developing an Integrated Algal BioRefinery in Columbus, New Mexico, to further its mission of creating sustainable energy solutions.

Endotis discovers, develops, and manufactures cardiovascular therapeutics. The company also discovers and develops small-glyco drugs for applications in thrombosis, oncology, and hematology areas. Its portfolio of products includes EP217609, a neutralizable anti-coagulant for managing extracorporeal blood circulation during open-heart surgery; FondaParinux, an injectable drug for the prevention and treatment of venous thromboembolism; and an oral anti-coagulant for stroke prevention in atrial fibrillation. Endotis was founded in 2003 and is based in Romainville, France.

Senexis is operates as a small-molecule drug discovery company, engages in discovering compounds for the treatment of ageing-related diseases resulting from the toxicity of amyloid-like proteins. The company offers small molecule inhibitors of amyloid aggregation and toxicity as therapeutic agents to inhibit the pathogenic process of protein misfolding, amyloid-related toxicity, and inflammation.

Novacta Biosystems Ltd, founded in 2003, specializes in the development of biopharmaceuticals aimed at treating bacterial infections, particularly those caused by drug-resistant strains. The company employs a dual business model that combines biocatalysis and microbial pathway engineering services with the discovery and development of novel small peptide molecules known as lantibiotics. These innovative therapies target various bacterial infections, including Clostridium difficile. By leveraging the expertise of GSK's Biotransformation and Natural Products scientific team, Novacta has established a robust infectious disease therapeutic pipeline, focusing on delivering effective anti-infective solutions.

Fovea Pharmaceuticals is a French biopharmaceutical company based in Paris, specializing in the discovery and development of drugs for ocular diseases. Founded in 2005, the company focuses on addressing various eye conditions, including allergic conjunctivitis, diabetic macular edema, and retinitis pigmentosa. Its product portfolio includes FOV1101 Prednisporin for allergic conjunctivitis, a proprietary plasma kallikrein-kinin inhibitor known as FOV2302 for hereditary angioedema, FOV2304 for diabetic macular edema, and FOV2501, an intravitreal formulation targeting retinitis pigmentosa and potentially dry age-related macular degeneration. As of October 30, 2009, Fovea operates as a subsidiary of Sanofi.

Sentinel Oncology Limited is a drug discovery company based in Cambridge, United Kingdom, founded in 2005. The company focuses on developing and commercializing therapeutics aimed at treating cancer, particularly for patients facing unmet medical needs. Sentinel Oncology's research and development pipeline includes innovative programs such as a treatment targeting Checkpoint Kinase 1, which is activated in response to DNA damage and replication stress, and a novel approach to treating metastatic breast cancer through the inhibition of S6K1. The company is advancing a strategy known as "Targeted Synergy," designed to enhance the therapeutic index by delivering drug effects directly to tumors. By fostering partnerships with the biotechnology and pharmaceutical industries, Sentinel Oncology aims to maximize the value of its drug candidates and contribute to improved cancer treatments.

Lectus Therapeutics Limited is a UK-based pharmaceutical company dedicated to drug discovery and development, specializing in next-generation ion channel modulators. The company aims to create a robust pipeline of first-in-class therapeutics, primarily targeting pain management and urinary bladder disorders. Utilizing proprietary proteomics technology, Lectus Therapeutics focuses on developing innovative treatments for various conditions, including angina, asthma, and epilepsy, alongside its core areas of interest. Through its commitment to advancing ion channel therapeutics, the company seeks to address unmet medical needs in the pharmaceutical landscape.

Xtera Communications, Inc. was a provider of optical transport solutions, specializing in Raman amplification-enabled systems for terrestrial and submarine networks. Founded in 1998 and headquartered in Allen, Texas, the company catered to telecommunications service providers, content service providers, enterprises, and government entities globally. Xtera offered a range of products and services, including un-repeatered and repeatered optical systems, designed to enhance network reach and capacity. Its solutions were tailored to meet individual customer needs, encompassing full turnkey systems, open architecture designs, and specific product supply. Despite its previous success in expanding its customer base and product portfolio, Xtera faced financial difficulties that led to its Chapter 11 bankruptcy filing in November 2016, which was later converted to Chapter 7 liquidation in February 2017.

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.

Kuur Therapeutics Limited is a biopharmaceutical company focused on developing, manufacturing, and commercializing CAR-NKT cell immunotherapies for cancer treatment. The company is advancing a pipeline of immune cell products, including KUR-501 for neuroblastoma, KUR-502 for hematological malignancies, and KUR-503 for liver cancer. Kuur Therapeutics specializes in engineered off-the-shelf CAR-NKT cell therapies that leverage the natural biology of a specific subset of cytotoxic T cells known as natural killer T cells. This innovative approach aims to provide effective treatment options for a wide range of solid and hematological tumors. The company conducts clinical trials to demonstrate the efficacy of its CAR-NKT cell products, thereby striving to transform cancer care. Founded in 2005 and based in London, Kuur Therapeutics was previously known as Cell Medica Limited before its rebranding in February 2020.